Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine, Treatment Expectation, and fMRI in Acute Major Depressive Disorder
DRKS00024815Phase 3Completed
- Sponsor
- Philipps-Universität Marburg
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of esketamine in major depressive disorder (MDD) (4 arms), sponsored by Philipps-Universität Marburg. Started Mar 2021; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on DRKS00024815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00024815.